SterneJACSavovicJPageMJElbersRGBlencoweNSBoutronIet alRob 2: a revised tool for assessing risk of bias in randomised trials
Further in vivo studies using mice demonstrated that, while Cmp2 failed to prominently enhance glucose-mediated insulin release when compared with the more potent peptidic drugs exenatide and liraglutide, it did nevertheless significantly decrease the overall glucose excursion (Irwin et al ., 2010)
Off-label benefits of GLP-1s are also being evaluated, some of which include improvement in inflammation and arthritis issues, metabolic disorders, addiction disorders (gambling, alcoholism, drugs) and possible benefits for hormone-driven cancers
For more context, the PubMed Central has provide detailed overviews of GLP-1 class medications in their study, Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes
Retatrutide shows none of these characteristics